Study Of GW679769 In Major Depressive Disorder
Study Of GW679769 In Major Depressive Disorder
This is a placebo-controlled, fixed dose study that will evaluate the efficacy and safety of
 GW679769 in subjects with major depressive disorder.
Inclusion criteria:

 -  Subjects must have the ability to comprehend the key components of the consent form.

 -  Subject must have met DSM-IV-TR (Diagnostic and Statistical Manual of Mental
 Disorders, Fourth Edition, Text Revision) criteria for current MDE (major depressive
 episode) for at least 8 weeks prior to the Screening Visit.

 -  If female, subjects must be practicing an acceptable method of birth control.

 -  Subjects must have rating scores as outlined.

 Exclusion criteria:

 -  Subjects whose symptoms of the MDE are better accounted for by another diagnosis.

 -  Subjects with a history of schizophrenia, schizoaffective disorders or bipolar
 disorder.

 -  Subjects have a positive urine test for illicit drug use and/or a history of substance
 abuse or alcohol dependence within the past 12 months.

 -  Subjects with an unstable medical disorder.

 -  If female, pregnant or lactating.

 -  Subjects who have received ECT (electroconvulsive therapy) or TMS (transcranial
 magnetic stimulation) within the 6 months preceding screening or who have ever been
 homicidal.